Drugs / PY159
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04682431 | Nov 2020 → Aug 2023 | breast cancer, colorectal cancer, female reproductive organ cancer, gastric adenocarcinoma +3 | Ikena Oncology | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PY159 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04682431 ↗ |
| Route | Intravenous | “PY159 dose level 1 IV administration” NCT04682431 ↗ |